Mark Timney joined The Medicines Company in December 2018 as Chief Executive Officer and as a Director. Mark is a healthcare leader with over 25 years of biopharmaceutical industry experience in multi-national companies. At Merck & Co, Mark led organizations of increasing importance and size, including President US, President Japan and President of Global Primary Care. In these roles, he launched multiple products, many in the cardiovascular therapeutic area, led large organizations of up to 8,000 employees, and was involved in a number of important strategic transactions. After leaving Merck, Mark served as the CEO of Purdue Pharmaceuticals and formed a company advising healthcare companies. Before joining Merck, he spent 8 years working at numerous multinational pharmaceutical companies, including Zeneca Group, ICI Pharmaceuticals and Roussel Labs. Mark received a bachelor’s degree in Sports Studies (majoring in Marketing) from Newcastle Polytechnic (now Northumbria University) in Newcastle in the United Kingdom.
Clive A. Meanwell has been a director since 1996. He has served as our chief executive officer since February 2012, our chief executive officer and president from October 2009 to February 2012, as our chief executive officer from August 2004 to October 2009, as our president from August 2004 to December 2004, our executive chairman from September 2001 to August 2004 and as our chief executive officer and president from 1996 to September 2001. Dr. Meanwell was also chairman of our board from September 2001 to August 2015. From 1995 to 1996, Dr. Meanwell was a partner and managing director at MPM Capital, L.P., a venture capital firm. From 1986 to 1995, Dr. Meanwell held various positions at Hoffmann-La Roche, Inc., a pharmaceutical company, including senior vice president from 1992 to 1995, vice president from 1991 to 1992 and director of product development from 1986 to 1991. Dr. Meanwell received an M.D. (British equivalent MB ChB) and a Ph.D. (British equivalent MD hons) from the University of Birmingham, United Kingdom.
Chris Visioli joined The Medicines Company in June 2003. He has worked in a variety of leadership roles in the organization including business development, finance, investor relations, strategy, planning, and business leadership of the anti-platelet team. Chris has led many efforts in the organization to acquire products and establish partnerships in addition to leading long-term strategy and financial planning work. Prior to joining MDCO, Chris was a management consultant for Ernst & Young. Chris holds a BS in electrical engineering from Cornell University and an MBA from Columbia Business School.
Chris Cox joined The Medicines Company (MDCO) in February 2016 as Executive Vice President and Chief Corporate Development Officer. Prior to joining MDCO, Chris spent over 20 years as a corporate attorney, most recently at Cadwalader, Wickersham & Taft LLP, where he was Co-Chair of the Firm’s Corporate Group and a member of its Management Committee. He joined Cadwalader in January 2012. Previously, he was a Partner at Cahill Gordon & Reindel LLP. Chris has extensive experience in a wide array of corporate, financial and business-related matters, including mergers and acquisitions, joint ventures, restructurings, spin-offs and IP licensing and monetization transactions. He has been selected by The American Lawyer as a “Dealmaker of the Year” and was named an M&A Atlas "Top 50 Global M&A Lawyer." He has also been recognized for his work in mergers, acquisitions and buyouts by Chambers and The Legal 500 and has been named a leading lawyer by the Lawdragon 500 Annual Guide. Chris has been a Director of Datawatch Corporation since August 21, 2012. He received a B.S. and J.D. from the University of Missouri, where he was a member of the Missouri Law Review.
Dr. Stephanie Plent is an Executive Vice President and Chief Value Officer at The Medicines Company. She is responsible for the global health economic development, reimbursement, market access and outcomes research for developing compounds as well as marketed products.
Stephanie joined The Medicines Company in July 2000 to build an economic and medical policy function. She became Vice President of Medical Affairs in 2003 then managed Phase IV programs and pediatric initiatives. In 2008 she led the expansion of bivalirudin into European markets working with the reimbursement agencies to gain positive HTA’s and reimbursement across the European markets.
Stephanie received her medical degree from the Royal Free Hospital, London UK and completed her general surgical residency at St. Bartholomew's Hospital UK. Since moving to the US she worked in the Health Care Practice of the consultancy company, Arthur D. Little, Cambridge MA and then for six years at Aetna Insurance, developing cardiac centers of excellence programs in conjunction with major cardiovascular hospitals and then launched national disease management programs for asthma, diabetes, heart failure and back pain management.
Stephen Rodin has been general counsel and secretary of The Medicines Company since March 2014. Previously he served as the Company's deputy general counsel from 2010 to 2014 and associate general counsel from 2007 to 2010. Before joining The Medicines Company, Steve was an attorney at the law firm of Proskauer Rose LLP in New York where his practice focused on corporate, commercial and securities law. Steve received an A.B. from Georgetown University and his J.D. from Vanderbilt University Law School.